Article
Lipidomics reveals biomarkers of the efficacy of first-line ICIs therapy combined with chemotherapy in NSCLC
2024-12-26
Abstract excerpt
<title>Abstract</title> <p>Immune checkpoint inhibitors (ICIs) plus chemotherapy have become the first-line standard therapy for patients with the gene-negative advanced non-small cell lung cancer (NSCLC). There is a lack of reliable biomarkers to predict treatment outcomes. This study aimed to identify relevant lipids that can predict treatment outcomes in NSCLC patients receiving first-line ICIs plus chemothera...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 7e025140-9836-598c-b63e-4567c73d2c01
- DOI
- 10.21203/rs.3.rs-5662148/v1
